Synergy of BID with doxorubicin in the killing of cancer cells

Orzechowska,Emilia Joanna; Girstun,Agnieszka; Staron,Krzysztof; Trzcinska-Danielewicz,Joanna

doi:10.3892/or.2015.3841

Synergy of BID with doxorubicin in the killing of cancer cells

Authors:
- Emilia Joanna Orzechowska
- Agnieszka Girstun
- Krzysztof Staron
- Joanna Trzcinska-Danielewicz
View Affiliations

Affiliations: Department of Molecular Biology, Institute of Biochemistry, Faculty of Biology, University of Warsaw, 02-096 Warsaw, Poland
Published online on: March 9, 2015 https://doi.org/10.3892/or.2015.3841
Pages: 2143-2150
Copyright: © Orzechowska et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Overexpression of the BH3-interacting domain death agonist (BID) protein sensitizes certain cancer cell lines to apoptosis induced by anticancer agents, particularly by those acting through death receptors (e.g. TRAIL). Previously, we showed that recombinant BID fused with TAT cell penetrating peptide (TAT-BID) allowed for controlled delivery of BID to different cancer cell lines and moderately sensitized some of them to TRAIL or slightly to camptothecin. In the present study, we showed that TAT-BID delivered to HeLa cells strongly sensitized them to doxorubicin, as identified by cell viability and apoptosis assays. Another cell line sensitized to doxorubicin was PC3, whereas A549 and LNCaP cells were sensitized moderately or not at all, respectively. Sensitization was more pronounced at 1 µM doxorubicin administered for 48 h than for lower doses and shorter treatments. TAT-BID and doxorubicin may thus be considered as a potential therapeutic combination for cervical carcinoma and advanced prostate cancer treatment.

View Figures

View References

1	Kantari C and Walczak H: Caspase-8 and Bid: Caught in the act between death receptors and mitochondria. Biochim Biophys Acta. 1813:558–563. 2011. View Article : Google Scholar : PubMed/NCBI
2	Liu Y, Bertram CC, Shi Q and Zinkel SS: Proapoptotic Bid mediates the Atr-directed DNA damage response to replicative stress. Cell Death Differ. 18:841–852. 2011. View Article : Google Scholar :
3	Song G, Chen GG, Chau DKF, Miao J and Lai PBS: Bid exhibits S phase checkpoint activation and plays a pro-apoptotic role in response to etoposide-induced DNA damage in hepatocellular carcinoma cells. Apoptosis. 13:693–701. 2008. View Article : Google Scholar : PubMed/NCBI
4	Tsuno T, Mejido J, Zhao T, Phillips T, Myers TG, Bekisz J and Zoon KC: BID is a critical factor controlling cell viability regulated by IFN-α. J Immunother. 35:23–31. 2012. View Article : Google Scholar
5	Goncharenko-Khaider N, Lane D, Matte I, Rancourt C and Piche A: The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene. 29:5523–5536. 2010. View Article : Google Scholar : PubMed/NCBI
6	Miao J, Chen GG, Chun SY, Yun JP, Chak EC, Ho RL and Lai PB: Adenovirus-mediated tBid overexpression results in therapeutic effects on p53-resistant hepatocellular carcinoma. Int J Cancer. 119:1985–1993. 2006. View Article : Google Scholar : PubMed/NCBI
7	Fukazawa T, Walter B and Owen-Schaub LB: Adenoviral Bid overexpression induces caspase-dependent cleavage of truncated Bid and p53-independent apoptosis in human non-small cell lung cancers. J Biol Chem. 278:25428–25434. 2003. View Article : Google Scholar : PubMed/NCBI
8	Li Y, Dai C, Li J, Wang W and Song G: Bid-overexpression regulates proliferation and phosphorylation of Akt and MAPKs in response to etoposide-induced DNA damage in hepatocellular carcinoma cells. Onco Targets Ther. 5:279–286. 2012.PubMed/NCBI
9	Orzechowska EJ, Kozlowska E, Czubaty A, Kozlowski P, Staron K and Trzcinska-Danielewicz J: Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis. BMC Cancer. 14:7712014. View Article : Google Scholar : PubMed/NCBI
10	Tacara O, Sriamornsak P and Dass CR: Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 65:157–170. 2012. View Article : Google Scholar
11	Yang F, Teves SS, Kemp CJ and Henikoff S: Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta. 1845.84–89. 2014.
12	Leung KL and Wang TT: Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Basic Cancer Res Treat. 55:73–83. 1999. View Article : Google Scholar
13	Watanabe M, Naraba H, Sakyo T and Kitagawa T: DNA damage-induced modulation of GLUT3 expression is mediated through p53-independent extracellular signal-regulated kinase signaling in HeLa cells. Mol Cancer Res. 8:1547–1557. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kelly MM, Hoel BD and Voelkel-Johnson C: Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther. 1:520–527. 2002. View Article : Google Scholar : PubMed/NCBI
15	Kang J, Bu J, Hao Y and Chen F: Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Prostate Cancer Prostatic Dis. 8:274–279. 2005. View Article : Google Scholar : PubMed/NCBI
16	Sánchez C, Mendoza P, Contreras HR, Vergara J, McCubrey JA, Huidobro C and Castellón EA: Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate. 69:1448–1459. 2009. View Article : Google Scholar : PubMed/NCBI
17	Wong FC, Woo CC, Hsu A, Kwong B and Tan BK: The anticancer activities of Vernonia amygdalina extract in human breast cancer cell lines are mediated through caspase-dependent and p53-independent pathways. PLoS One. 8:e780212013. View Article : Google Scholar
18	Desagher S, Osen-Sand A, Montessuit S, Magnenat E, Vilbois F, Hochmann A, Journot L, Antonsson B and Martinou JC: Phosphorylation of Bid by casein kinases I and II regulates its cleavage by caspase 8. Mol Cell. 8:601–611. 2001. View Article : Google Scholar : PubMed/NCBI
19	Lee SJ, Hwang SO, Noh EJ, Kim DU, Nam M, Kim JH, Nam JH and Hoe KL: Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells. Exp Mol Med. 46:e762014. View Article : Google Scholar : PubMed/NCBI
20	Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R and Olumi AF: Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res. 64:7086–7091. 2004. View Article : Google Scholar : PubMed/NCBI
21	He Z, Zhang Y, Mehta SK, Pierson DL, Wu H and Rohde LH: Expression profile of apoptosis related genes and radio-sensitivity of prostate cancer cells. J Radiat Res. 52:743–751. 2011. View Article : Google Scholar : PubMed/NCBI
22	Hait WN and Yang JM: The individualization of cancer therapy: the unexpected role of p53. Trans Am Clin Climatol Assoc. 117:85–101. 2006.
23	Bien S, Rimmbach C, Neumann H, Niessen J, Reimer E, Ritter CA, Rosskopf D, Cinatl J, Michaelis M, Schroeder HW and Kroemer HK: Doxorubicin-induced cell death requires cathepsin B in HeLa cells. Biochem Pharmacol. 80:1466–1477. 2010. View Article : Google Scholar : PubMed/NCBI
24	Howells CC, Baumann WT, Samuels DC and Finkielstein CV: The Bcl-2-associated death promoter (BAD) lowers the threshold at which the Bcl-2-interacting domain death agonist (BID) triggers mitochondria disintegration. J Theor Biol. 271:114–123. 2011. View Article : Google Scholar